Physician profile
Katherine E Twombley
NPI 1356532311
$64,324.27
in general payments reported to CMS, 2019-2025
6 companies · $6,917 in 2025
The $6,917 reported for 2025 was more than what 90% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $6,723 · 2021: $6,347 · 2022: $7,610 · 2023: $13K · 2024: $23K · 2025: $6,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Honoraria: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,525 · Travel and Lodging: $5,354 · Food and Beverage: $1,643 · Entertainment: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,498.00 |
| Honoraria | $10,842.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,525.00 |
| Travel and Lodging | $5,353.70 |
| Food and Beverage | $1,643.40 |
| Entertainment | $162.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $26,234.92 | 2021-2023 | Procysbi |
| Alexion Pharmaceuticals, INC. | $22,122.16 | 2021-2025 | Ultomiris |
| Kaneka Medical America LLC | $9,005.62 | 2019-2024 | |
| Travere Therapeutics, INC. | $6,194.52 | 2025 | Filspari |
| Argenx US, INC. | $600.00 | 2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $167.05 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Twombley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.